Dr.Hitesh Saraogi (@hit2cupid) profile picture

Diabetologist, Obesity specialist with interest in Endocrinology. SCOPE certified Obesity. Royal College of Physician (UK) certified in Endocrinology & Diabetes

Delhi- NCR
Joined June 2009
Dr.Hitesh Saraogi retweeted
Lifestyle Modification as Foundational Therapy in Diabetes – Reclaiming Its Role in the Era of New Pharmacotherapy Authors: Hitesh Saraogi, Indrashis Mukherjee, Ninad Gor, Vikranti Sailor, Nadia Phirozmand, Meghanad Meher, Surender Mittal, Kshitij Kumar, Mudrik Patel and Soumyaranjan Mohanty. International Journal of Drug Delivery Technology. 2026;16(88s):359–371. 🔬 15 High-Impact Clinical Pearls 1️⃣ Newer drugs are powerful, but lifestyle remains foundational. GLP-1 receptor agonists, dual incretin therapies and emerging triple agonists have transformed diabetes management. However, dietary quality, physical activity, sleep, stress and weight management remain essential for sustained cardiometabolic benefits. 2️⃣ Diabetes remission is a realistic therapeutic goal in selected patients. The review highlights remission rates of 46% at one year in DiRECT and 61% in DIADEM-I. These results were achieved in selected populations receiving intensive interventions and should not be generalized to every patient. Clinical message: Early T2D deserves a structured remission-oriented discussion, particularly when excess adiposity is present. 3️⃣ Weight loss is metabolic treatment, not merely cosmetic improvement. A sustained 5–10% reduction in body weight can meaningfully improve glycaemia, insulin sensitivity and cardiovascular risk factors. Greater weight loss may increase the likelihood of remission, especially in early T2D. 4️⃣ The 10–10–10 rule deserves a place in diabetes prescriptions. Encourage three 10-minute walks, one after each major meal. Postprandial muscle activity increases glucose utilization and may reduce post-meal glycaemic excursions. 5️⃣ Resistance training is as important as walking. Skeletal muscle is a major site of insulin-mediated glucose disposal. The review emphasizes combining aerobic exercise with resistance training 2–3 times weekly. Preserving muscle becomes particularly important during ageing and weight-loss therapy. 6️⃣ Break prolonged sitting every 30 minutes. A patient who walks for 30 minutes but remains sedentary throughout the day still has substantial inactivity exposure. Brief movement breaks are a practical additional intervention. 7️⃣ Dietary pattern matters more than fashionable diet labels. Mediterranean, DASH and fibre-rich plant-based dietary patterns show favourable metabolic outcomes. Ultra-processed foods, refined carbohydrates, sugary beverages and processed meats are associated with poorer cardiometabolic health. The sustainable diet is more useful than the theoretically perfect diet that cannot be maintained. 8️⃣ GLP-1-based weight loss requires attention to muscle preservation. The review discusses reductions in measured lean soft tissue during incretin-associated weight loss. Resistance training, adequate dietary protein and functional assessment should accompany obesity pharmacotherapy. Importantly, loss of DEXA-measured lean mass does not necessarily represent equivalent loss of functional skeletal muscle. 9️⃣ Sleep is an often-neglected metabolic intervention. Short sleep, circadian disruption and irregular sleep schedules are associated with insulin resistance and increased diabetes risk. For most adults, approximately 7–9 hours of adequate-quality sleep is a reasonable target. 🔟 Consider obstructive sleep apnoea in difficult-to-control diabetes. The review highlights the frequent coexistence of OSA and T2D, particularly with obesity. Snoring, witnessed apnoea, daytime sleepiness and resistant hypertension should prompt evaluation. CPAP has established benefits for symptomatic OSA, although improvements in HbA1c are variable. Saraogi H, Mukherjee I, Gor N, et al. Lifestyle Modification as Foundational Therapy in Diabetes: Reclaiming Its Role in the Era of New Pharmacotherapy. IJDDT. 2026;16(88s):359–371. DOI: 10.25258/ijddt.16.88s.26. NEXT
2
5
8
859
I watched "Graves of the Fireflies", and I was left with a grief that is difficult to put into words. Around the world children are paying the price for a war they never started. They deserve love. #GravesOfTheFireflies #ChildrenOfWar #StopWar #Peace #WarAndConflict #Humanity
9
Dr.Hitesh Saraogi retweeted
Leading diabetes doctor Professor Partha Kar has received a lifetime achievement award for his work to promote race equality in the NHS. buff.ly/A6ibGdA
48
77
14
559
64,646
Dr.Hitesh Saraogi retweeted
🔴 CME INDIA | CLINICAL PEARLS LADA in Routine Practice: From Misdiagnosis to Precision Care Authors: Hitesh Saraogi — Dhanwantari Hospital, Ghaziabad, India; Wahid Khan — Apollo Superspeciality Hospital, Muscat, Oman. Top 12 Clinical Pearls 1. LADA is the diabetes we frequently call “Type 2” too early. It is an autoimmune diabetes with gradual β-cell destruction, often initially resembling T2DM because insulin may not be required at diagnosis. 2. The burden is clinically important. The review estimates that approximately 4–14% of people initially diagnosed with T2DM may actually have an autoimmune phenotype consistent with LADA. 3. Think of diabetes as a spectrum rather than rigid boxes. LADA occupies the middle ground between classical T1DM and T2DM: autoimmunity like T1DM, but slower β-cell loss and often some insulin resistance like T2DM. The authors’ schematic nicely illustrates this continuum. 4. When should the physician suspect LADA? Reconsider the diagnosis of T2DM when an adult has relatively young onset, lower/normal BMI, unexpected weight loss, autoimmune background, rapidly worsening HbA1c, or an unexpectedly early requirement for insulin despite apparently appropriate oral therapy. 5. GAD antibody is the key first antibody. GADA is the most commonly detected islet autoantibody in LADA. Additional antibodies can improve characterization when clinical suspicion remains high. 6. C-peptide tells you how much β-cell reserve remains. Autoantibodies establish autoimmunity; C-peptide provides complementary information about residual endogenous insulin secretion and can help guide therapeutic intensity. The article specifically highlights both GAD antibodies and C-peptide as central to precision classification. 7. A single phenotype does not describe all LADA. β-cell decline is heterogeneous. Some patients rapidly become insulin dependent, while others retain useful insulin secretion for years. This explains why LADA is easily missed in routine practice. 8. Poor response to conventional T2DM therapy is a diagnostic clue—not merely “noncompliance.” When glycemia progressively deteriorates despite reasonable lifestyle measures and glucose-lowering therapy, revisit the type of diabetes, not just the dose of drugs. 9. Avoid therapeutic inertia while β-cells disappear. Conventional T2DM algorithms may not adequately address the progressive autoimmune β-cell loss of LADA. Earlier recognition allows treatment to be individualized rather than repeatedly escalating oral drugs. 10. Insulin should not be viewed as “failure.” Progressive insulin deficiency is intrinsic to the biology of LADA. The timing of insulin should therefore be driven by glycemia, symptoms and β-cell reserve rather than waiting for severe metabolic deterioration. 11. Be cautious with drugs in patients becoming insulin deficient. Particularly when C-peptide is low or declining, therapies that can expose an insulin-deficient patient to ketosis deserve extra caution. The clinical priority is to recognize impending insulin dependence before severe hyperglycemia or ketoacidosis occurs. 12. Precision diabetes care begins with correct classification. 🧬 Adult-onset diabetes should not automatically equal T2DM. Combining clinical phenotype + islet autoantibodies + C-peptide can move management from empirical glucose lowering toward pathophysiology-based treatment. The authors emphasize that standardized diagnostic criteria and prospective trials are still needed. 🧠 CME INDIA PRACTICE MESSAGE Adult “T2DM” + atypical phenotype / early treatment failure → Think LADA → Check GADA ± other islet antibodies + C-peptide → Reclassify → Individualize therapy → Do not delay insulin when β-cell reserve is failing. One-line pearl: > When an adult with presumed Type 2 diabetes behaves unlike Type 2 diabetes, question the diagnosis before adding another tablet. link.springer.com/article/10…
5
17
824
Dr.Hitesh Saraogi retweeted
Denied entry at PVR with my emergency hypo kit despite explaining I have #Type1diabetes The manager even said, "If you have this condition, you shouldn't come to watch a movie." This is discrimination. Your staff need urgent awareness training. @_PVRCinemas
282
1,829
97
15,740
995,608
The 13th #JDCON2026 was successfully inaugurated in the presence of Dr. Vinky Rughwani President, Maharashtra Medical Council, Nagpur, who graced the occasion as the Chief Guest. Together,we strive for healthier futures and stronger support systems for every child with Type 1DM
1
2
4
176
Replying to @NbeIndia
@NbeIndia @attilivss @abhijatsheth I attended the AI Course with more than 75% attendance, fulfilling the eligibility criteria communicated for assessment. Despite this, my portal currently shows that I am not eligible for the assessment I respectfully request NBE to review this
1
29
@NbeIndia @attilivss @abhijatsheth i have already mailed twice with no response. kindly review this and help me with the same and there is not other way to contact you.
5
I am delighted to share that the @Lipidaoi1 LAI Expert Consensus Statement Part 4 has been 3rd top downloaded article all time of Journal of Clinical Lipidology (JCL). @Hragy
1
33
Dr.Hitesh Saraogi retweeted
Excellent Interview with Shobha John (Rediff.com). Based on my book "Smart #Calories and Common Sense" Bestseller on @Amazon. Key points: fad diets, influencers incorrect diet claims, and what is balanced diet
🤖 Made with AI
3
8
399
One of the best books written on the Indian diet with all the facts and myths associated with it, which all physicians face in day to day practice. I would like to congratulate and thank @docanoopmisra Sir for compiling this book on the Indian diet.
2
5
258
Dr.Hitesh Saraogi retweeted
Taking care of our patients in a holistic manner: #metabolic associated #chronic #kidney #disease A must read for #health care professionals @ASNKidney @NephJC @nephrologynow @MetabolicFactor @MetabolicAlpha @MetabolicUncle @metaboliam
♨️mCKD 🔥Combined kidney damage with interconnected metabolic mechanisms be diagnosed as a single entity- metabolic-associated CKD (mCKD) 🔗10.25259/IJN_524_2025 Contd..
1
3
8
723
Dr.Hitesh Saraogi retweeted
Most of us have a relative or parent who suffered from a hip or spine fracture in their old age. Bone #fractures without significant injury are called #fragilityfractures, and are increasingly common beyond 60 years of age. As the Indian population ages, fragility "osteoporotic" fractures have become a serious concern. Many such fractures are preventable if we pay attention. Conversation with orthopedic surgeon Dr Naman Wahl where we talk about #osteoporosis prevention and treatment. In easy Hindi and English- mixed😊 @IndiaESI @delhiendo @ISBMRTweets @iofbonehealth youtu.be/S_EFz9rMs70?si=e5tP…
1
6
1
33
2,680
Still learning. Still growing. Still becoming the best version of myself. ✨ “Progress is not about being perfect every day, it’s about showing up and improving one step at a time.” 🌱 #dtech #diabetes #rssdi
1
8
Dr.Hitesh Saraogi retweeted
When I saw this video, my first thought was that the earth, very often, sends us messages. This tree, facing constant winds, is still standing, & has neither fallen nor been uprooted. Instead it’s been shaped by it. And developed its own unique aesthetic & identity. We have to recognize & accept that tough times & tragedies are part of the journey. They don’t define us, they simply give us our own unique personalities & capacities… #MondayMotivation
233
1,435
50
10,435
421,770
Dr.Hitesh Saraogi retweeted
1
2
14
745
Dr.Hitesh Saraogi retweeted
Session Spotlight | Gama Hall "Technology Advances in Diabetes Pregnancy: Right Technology, Right Person, Right Time" An insightful talk by Dr. Hitesh Saraogi (New Delhi) Moderated by the visionary Dr. Jothydev Kesavadev (Thiruvananthapuram) #DTechCon2025 #DiabetesInPregnancy
1
76